Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
10 result(s) found, displaying 1 to 10
-
TGA laboratory testing reportsThe Therapeutic Goods Administration (TGA) is issuing a safety advisory regarding imported unregistered melatonin products following testing by TGA Laboratories.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 6 March 2025
-
TGA laboratory testing reportsThis survey focused on single-ingredient vitamin D3 products with high sales volumes in Australia between January and December 2023. The TGA tested 13 of the top-selling products, which were supplied by nine different sponsors.
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
TGA laboratory testing reportsThis testing project was designed to assess compliance with the new Standard
-
Corporate reportsAbout compositional guidelines for ingredients permitted for use in listed medicines.
-
Meeting statementsAdvisory Committee on Complementary Medicines Meeting 17 meeting statement